Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer: A systematic review

Vollenbrock, Sophie E; Voncken, Francine E.M.; Bartels, Lambertus W.; Bartels‐Rutten, Annemarieke

doi:10.1016/j.radonc.2019.07.006

Cited by 19 publications

(14 citation statements)

References 63 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other studies looking at different tumors have reported similar results ( Amodeo et al, 2018 , Vollenbrock et al, 2020 , Chen et al, 2019 ) and it is likely that the relative change in ADC or percentage change in ADC is the more promising measure as this has the advantage that relative measurements suffer less from practice variations when compared to absolute values. DWI detects changes in the microstructure of biological tissues and ADC is sensitive to the dynamic motion of water particularly with treatment, hence the potential to be more useful as a marker of response during treatment, as opposed to before treatment.…”

Section: Discussionmentioning

confidence: 69%

“…A recent review found that ADC values detected pre-therapy in cervical cancers could not be used to predict therapy response ( MEYER et al, 2021 ), but our team felt that the more appropriate marker would be the change in ADC with treatment as DWI is sensitive to the dynamic water movement within tumors that occurs with therapy, more so than just absolute values documented before the start of treatment. This theory has been borne out in other solid tumors as well ( Amodeo et al, 2018 , Vollenbrock et al, 2020 ). Hence, it is entirely more appropriate to perform a comprehensive review on ADC changes with treatment.…”

Section: Introductionmentioning

confidence: 87%

See 1 more Smart Citation

Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis

Harry

Persad

Bassaw

et al. 2021

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 87%

Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis

Harry

Persad

Bassaw

et al. 2021

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

“…Adding DW-MRI to gastroscopy and endosonographic ultrasound could improve the detection of residual tumor after neoadjuvant chemoradiotherapy [ 26 ]. A systematic review implied that DW-MRI used to evaluate response to chemoradiotherapy in esophageal cancer showed variable methods and results, and a large increase in ADC after two weeks of treatment seems most predictive for a good response [ 27 ]. Previous small sample studies have verified that a treatment-induced change in ADC during the first 2–3 weeks of nCRT is most predictive for a pathological complete response to nCRT in esophageal cancer patients [ 12 , 14 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

Sun²,

et al. 2021

Radiat Oncol

View full text Add to dashboard Cite

Background Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is a currently widely used strategy for locally advanced esophageal cancer (EC). However, the conventional imaging methods have certain deficiencies in the evaluation and prediction of the efficacy of nCRT. This study aimed to explore the value of functional imaging in predicting the response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced esophageal squamous cell carcinoma (ESCC). Methods Fifty-four patients diagnosed with locally advanced ESCC from August 2017 to September 2019 and treated with nCRT were retrospectively analyzed. DW-MRI scanning was performed before nCRT, at 10–15 fractions of radiotherapy, and 4–6 weeks after the completion of nCRT. 18F-FDG PET/CT scans were performed before nCRT and 4–6 weeks after the completion of nCRT. These 18F-FDG PET/CT and DW-MRI parameters and relative changes were compared between patients with pathological complete response (pCR) and non-pCR. Results A total of 8 of 54 patients (14.8%) were evaluated as disease progression in the preoperative assessment. The remaining forty-six patients underwent operations, and the pathological assessments of the surgical resection specimens demonstrated pathological complete response (pCR) in 10 patients (21.7%) and complete response of primary tumor (pCR-T) in 16 patients (34.8%). The change of metabolic tumor volume (∆MTV) and change of total lesion glycolysis (∆TLG) were significantly different between patients with pCR and non-pCR. The SUVmax-Tpost, MTV-Tpost, and TLG-Tpost of esophageal tumors in 18F-FDG PET/CT scans after neoadjuvant chemoradiotherapy and the ∆ SUVmax-T and ∆MTV-T were significantly different between pCR-T versus non-pCR-T patients. The esophageal tumor apparent diffusion coefficient (ADC) increased after nCRT; the ADCduring, ADCpost and ∆ADCduring were significantly different between pCR-T and non-pCR-T groups. ROC analyses showed that the model that combined ADCduring with TLG-Tpost had the highest AUC (0.914) for pCR-T prediction, with 90.0% and 86.4% sensitivity and specificity, respectively. Conclusion 18F-FDG PET/CT is useful for re-staging after nCRT and for surgical decision. Integrating parameters of 18F-FDG PET/CT and DW-MRI can identify pathological response of primary tumor to nCRT more accurately in ESCC.

show abstract

“…Since these measurements did not add to the accuracy of the set of diagnostic modalities in the preSANO trial, it was decided that they are not included in the preSINO trial protocol [8]. MRI is another promising modality, showing sensitivities up to 97% for detecting residual tumor after nCRT [30,31]. However, studies that find these high sensitivities all have poor corresponding specificities of at most 58%.…”

Section: Discussionmentioning

confidence: 99%

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study

et al. 2020

View full text Add to dashboard Cite

Background: After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete response (pCR) rates are being achieved especially in patients with squamous cell carcinoma (SCC). An active surveillance strategy has been proposed for SCC patients with clinically complete response (cCR) after nCRT. To justify omitting surgical resection, patients with residual disease should be accurately identified. The aim of this study is to assess the accuracy of response evaluations after nCRT based on the preSANO trial, including positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) with fine-needle aspiration (FNA) in patients with potentially curable esophageal SCC. Methods: Operable esophageal SCC patients who are planned to undergo nCRT according to the CROSS regimen and are planned to undergo surgery will be recruited from four Asian centers. Four to 6 weeks after completion of nCRT, patients will undergo a first clinical response evaluation (CRE-1) consisting of endoscopy with bite-on-bite biopsies. In patients without histological evidence of residual tumor (i.e. without positive biopsies), surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT, consisting of PET-CT, endoscopy with bite-on-bite biopsies and EUS with FNA. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy. Results of CRE-1 and CRE-2 as well as results of the three single diagnostic modalities will be correlated to pathological response in the resection specimen (gold standard) for calculation of sensitivity, specificity, negative predictive value and positive predictive value.

show abstract

Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer: A systematic review

Cited by 19 publications

References 63 publications

Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis

Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis

Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study

Contact Info

Product

Resources

About